Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 1Q

Total product sales were down 8% to $3.2 billion, partly reflecting the negative impact of foreign exchange. Sales in the U.S. were $2.5 billion (-10%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 1Q

1Q Revenues: $3.3 billion (-8%)

1Q Earnings: $1.0 billion (-7%)

Comments: Total product sales were down 8% to $3.2 billion, partly reflecting the negative impact of foreign exchange. Sales in the U.S. were $2.5 billion (-10%). International sales were $736 million (-2%). Worldwide sales of Aranesp were $626 million (-18%). Sales of Epogen were $565 million (+2%). Combined worldwide sales of Neulasta and Neupogen were down 1% to $1.1 billion. Sales of Enbrel were down 20% to $758 million. Sales of Sensipar were up 11% to $148 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters